Reaction Biology and Cisbio Sign Distribution Agreement
News Jan 17, 2014
RBC manufactures one of the largest collections of recombinant human epigenetic proteins. These proteins modulate genetic function in humans and are the subject of intense research in the pharmaceutical industry to validate them as targets for a new generation of cancer drugs. Cisbio develops and markets a broad selection of assays used worldwide by researchers in drug discovery. The company has recently expanded its product offering with very innovative solutions to assess epigenetic targets such as methyltransferases. The new agreement will give Cisbio worldwide rights to co-market and sell RBC’s proteins.
“RBC’s portfolio of epigenetic proteins is projected to grow to over 200 this year,” said Dr. Haiching Ma, RBC Chief Scientific Officer. “With more and more international interest, we felt a relationship with an outstanding distributor like Cisbio would bring these proteins to the widest possible client base.”
“We have been seeing increasing demand for high quality epigenetic proteins that can be included in the assays that we currently develop" added Patrick Seguin, VP Sales and Marketing. "RBC’s proteins have met all of our requirements for purity and activity levels, and this agreement represents one step forward in our goal to become a premier provider of epigenetic assays.”
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019